English
mitiglinide
Sign in to saveAlso known as Mitiglinide calcium hydrate, KAD-1229
Mitiglinide (INN, trade name Glufast) is a drug for the treatment of type 2 diabetes.
Research
163 papers- Mitiglinide: a novel agent for the treatment of type 2 diabetes mellitus.The Annals of pharmacotherapy · 2010
- Mitiglinide for type 2 diabetes treatment.Expert opinion on pharmacotherapy · 2013
- Mitiglinide: KAD 1229, S 21403.Drugs in R&D · 2004
- Mitiglinide: a rapid- and short-acting non-sulfonylurea insulinotropic agent for the treatment of type 2 diabetic patients.Expert opinion on pharmacotherapy · 2008
- [Mitiglinide (KAD-1229)].Nihon rinsho. Japanese journal of clinical medicine · 2002
via PubMed
~1 min read
Encyclopedic overview
4 sectionsContents
- Pharmacology
- Dosage
- References
- External links
Mitiglinide (INN, trade name Glufast) is a drug for the treatment of type 2 diabetes.
Mitiglinide belongs to the meglitinide (glinide) class of blood glucose-lowering drugs and is currently co-marketed in Japan by Kissei and Takeda. The North America rights to mitiglinide are held by Elixir Pharmaceuticals. Mitiglinide has not yet gained FDA approval.
Excerpted from Wikipedia’s “mitiglinide” article, available under the CC BY-SA 4.0 licence.